Abstract
Tobramycin, a new aminoglycoside antibiotic, penetrated the aqueous humor of human eyes after parenteral administration, either intramuscularly or intravenously, in 36 cataract patients with a presumably normal blood aqueous barrier. Tobramycin administered subconjunctivally to eyes with a normal blood aqueous barrier is capable of achieving therapeutic aqueous humor levels that exceed the minimal inhibitory concentration of most isolates of Pseudomonas and Staphylococcus. No adverse effects were noted in the subjects studied. This drug may be used in the treatment of acute ocular infections.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
